-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 24, Vertex Pharmaceuticals and Arbor Biotechnologies announced that the two parties will launch a new collaboration to use Arbor's proprietary CRISPR gene editing technology to enhance the development of innovative cell therapies for the treatment of serious diseases
.
Arbor was co-founded by renowned scholar Dr.
Feng Zhang with the aim of discovering new gene-editing proteins and developing "tailor-made" nuclease therapy for diseases based on these proteins
.
The company has discovered more than 60 nuclease families and more than 70 CRISPR transposases (transposases), which are 6 times and 30 times the number published in the literature
The new agreement between Arbor and Vertex builds on the partnership established between the two parties in 2018
.
According to this new cooperation agreement, Vertex will obtain the right to use Arbor's technology to research and develop ex vivo engineered cell therapies to develop fully differentiated, insulin-producing low-immune islet cells for the treatment of type 1 diabetes; and research and development A new generation method for the treatment of diseases such as sickle cell disease and beta thalassemia
Under the terms of the agreement, Arbor will receive an advance payment and is eligible for potential milestone payments of up to $1.
2 billion
.
In addition, Vertex will also pay tiered royalties for future net sales of any products that may result from this cooperation
Reference materials:
[1] Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies.
(The original text has been deleted)
